

REGISTERED No. M - 302
L.-7646



EXTRAORDINARY
PUBLISHED BY AUTHORITY

ISLAMABAD, WEDNESDAY, NOVEMBER 27, 2019

PART II

Statutory Notifications (S. R. O.)

GOVERNMENT OF PAKISTAN
MINISTRY OF NATIONAL HEALTH SERVICES,
REGULATIONS AND COORDINATION

(Drug Regulatory Authority of Pakistan)

NOTIFICATION

Islamabad, the 27th November, 2019

S.R.O. 1460(I)/2019.—In exercise of the powers conferred by section 23 of the Drug Regulatory Authority of Pakistan Act, 2012 (XXI of 2012), read with clause (a) of section 7 thereof and section 43 of the Drugs Act, 1976 (XXXI of 1976), the Drug Regulatory Authority of Pakistan, with the approval of the Federal Government, is pleased to direct that the following further amendments shall be made in the Drugs (Licensing, Registering and Advertising) Rules, 1976, the same having been previously published vide Notification No. S.R.O 1163(I)/2017, dated the 31st October, 2017, as required by sub-section (3) of the said section 43, namely:—

In the aforesaid Rules,—

(2637)

Price: Rs. 6.00

[1840(2019)/Ex.Gaz.]

- (1) in rule 8, in sub-rule (1), in clause (h), for the words “Deputy Director General”, the words “Additional Director” shall be substituted;
- (2) in rule 15, in sub-rule (1),—
 - (a) in clause (c), for the word “ten”, the word “eight” shall be substituted; and
 - (b) in clause (e), for the word “ten”, the word “eight” shall be substituted; and
- (3) in rule 16,—
 - (a) in clause (c),—
 - (i) in sub-clause (i), the word “ten”, the word “six” shall be substituted;
 - (ii) sub-clause (ii) shall be omitted;
 - (iii) in sub-clause (iii), the words “or sub-clause (ii)” shall be omitted;
 - (iv) in sub-clause (iii), amended as aforesaid, in the first proviso, for the word “medicine”, the words “pharmacy or microbiology or biotechnology” shall be substituted; and
 - (b) for clause (e), the following shall be substituted, namely:—
 - “(c) The Quality Control Department shall be independent of the manufacturing unit and its incharge shall be a whole time employee of the manufacturer and shall possess a degree in pharmacy and shall have minimum six years experience in testing of types of drugs intended to be manufactured or shall possess a master degree in chemistry and shall have minimum ten years experience in testing of types of drugs intended to be manufactured:

Provided that for pharmacological testing, there shall be an additional employee who shall possess a degree in pharmacy or a master degree in pharmacology and shall have minimum six years experience in testing of types of drugs intended to be manufactured and for

microbiological testing there shall be an additional employee who shall possess a degree in pharmacy or a master degree in microbiology and shall have minimum six years experience in testing of types of drugs intended to be manufactured:

Provided further that in the case of drugs specified in Schedule C, the Central Licensing Board may allow the applicant to make arrangements with some other institution approved by the Central Licensing Board for such tests to be regularly carried out on his behalf by that institution:

Provided also that there shall be an independent head of quality assurance for the quality assurance of the drugs being manufactured who shall possess a degree in pharmacy with seven years experience having minimum five years experience in quality control and testing of drugs;”.

[No. 1096-Dir(Lic)/DRAP.]

AAMAR LATIF,
Deputy Director (Legal Affairs).